Stock Events

Stock Events

Graybug Vision 

$5.5
18
+$5.06+1,148.86% Monday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
118.59M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

8MarExpected
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
-0.48
-0.44
-0.4
-0.36
Expected EPS
-0.45
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
0Revenue
-35.61MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 10.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GRAY. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in the development of small molecule drugs for serious diseases, including inflammatory conditions, which puts it in direct competition with CalciMedica's focus on treatments for acute pancreatitis and other inflammatory diseases.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, but its expansion into other therapeutic areas, including inflammatory and respiratory diseases, makes it a competitor.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in areas including immunology and chronic inflammatory conditions, directly competing with CalciMedica's development of treatments for diseases with inflammatory components.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for inflammatory diseases, making it a competitor in the biopharmaceutical space targeting similar conditions as CalciMedica.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, with a significant focus on inflammatory diseases, positioning it as a competitor to CalciMedica.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, but its interest in expanding into other areas, including inflammatory diseases, makes it a potential competitor.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that operates across various segments, including pharmaceuticals that target inflammatory diseases, making it a competitor in the same therapeutic area as CalciMedica.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including inflammation and immunology, directly competing with CalciMedica's focus areas.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for a broad range of health conditions, including inflammatory diseases, making it a competitor.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in several key therapeutic areas, including respiratory, inflammation, and autoimmunity, positioning it as a competitor to CalciMedica in the inflammation segment.

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Show more...
CEO
Employees
29
Country
US
ISIN
US38942Q1031

Listings

XNAS
US
CALC
BOATS
BOATS
CALC.BOATS

0 Comments

Share your thoughts

FAQ

What is Graybug Vision stock price today?▼
The current price of GRAY is $5.5 USD — it has increased by +1,148.86% in the past 24 hours. Watch Graybug Vision stock price performance more closely on the chart.
What is Graybug Vision stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Graybug Vision stocks are traded under the ticker GRAY.
What is Graybug Vision market cap?▼
Today Graybug Vision has the market capitalization of 118.59M
What is Graybug Vision revenue for the last year?▼
Graybug Vision revenue for the last year amounts to 0 USD.
What is Graybug Vision net income for the last year?▼
GRAY net income for the last year is -35.61M USD.
How many employees does Graybug Vision have?▼
As of April 02, 2026, the company has 29 employees.
In which sector is Graybug Vision located?▼
Graybug Vision operates in the Manufacturing sector.
When did Graybug Vision complete a stock split?▼
The last stock split for Graybug Vision was on March 20, 2023 with a ratio of 1:14.